Study of haemostasis in depressive patients treated with fluoxetine

✍ Scribed by Pascale Lainé-Cessac; Iran Shoaay; Jean-Bernard Garre; Valerie Glaud; Alain Turcant; Pierre Allain

• Publisher: John Wiley and Sons
• Year: 1998
• Tongue: English
• Weight: 103 KB
• Volume: 7
• Category: Article
• ISSN: 1053-8569
• DOI: 10.1002/(sici)1099-1557(199808)7:1+<s54::aid-pds345>3.0.co;2-z

✦ Synopsis

The object of this study was to investigate a possible pharmacological eect of ¯uoxetine on haemostatic function, with special attention on primary haemostasis, in order to explain haemorrhagic complications reported in some treated, depressed patients. The haemostatic function of depressive patients, who required ¯uoxetine therapy, was studied before and after 1 month of treatment with ¯uoxetine 20 or 40 mg daily. Exclusion criteria were: pregnancy, initial abnormal haemostatic function, history of coagulation abnormalities, treatment with drugs that interfere with haemostasis, and recent ¯uoxetine therapy. The following tests were performed: prothrombin time, partial thromboplastin time, thrombin time, plasma ®brinogen, platelet counts, bleeding time, platelet aggregation induced by ADP, epinephrine, ristocetin, collagen, arachidonic acid, and plasma determination of ¯uoxetine and nor¯uoxetine levels. Statistical analysis was performed by Wilcoxon paired sample, one-tailed test (a 0.05). Among 18 patients included, only eight completed the trial. The single statistically signi®cant dierence was a decreased velocity in platelet aggregation induced by epinephrine without increased bleeding time. The results failed to demonstrate any compromised haemostatic function after 20 mg daily ¯uoxetine therapy in patients with initial haemostatic function. However, the results suggest possible eects of ¯uoxetine on platelet adrenoreceptors.